Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So...what do you think?
So, I just happened to be on Google Italy, checking out Austep because I dislike it when my investments go down instead of up. So, I noticed that Austep was known for Wastewater treatment plants.
Austep is a Private Company, and one wonders if going public wouldn't help with expansion.
Read this article which provides more insight into the transaction. The magnitude of which gets lost in the legalese of the 8K:
http://www.aziendabanca.it/legal/banca-imi-nel-primo-project-financing-con-ebitda-garantito
Did you see this line?
In the context of restructuring, Banca IMI has granted four society also financed a new revolving credit facility to dispose of tax credits generated by the project management.
In other words, Management found a magic formula to utilize the tax credits as collateral.
I cannot help but think--call me crazy--that Austep may attempt a Reverse Takeover of Blue Sphere, which is certainly an attractive bargain after it, keep it as a separate entity, and then utilize it to finance growth in the US wastewater market, which is ripe for consolidation and privatization in the Trump era.
In addition, in Hickory, NC, Blue Sphere Water Technologies already has a foothold in the wastewater equipment universe. It is a private company founded in 2011, the same year that Elroy Amitzur--a wastewater treatment specialist and investor--came on board. Coincidence? Probably, but it would be a perfect fit for Austep.
http://bluespherewatertechnology.com.htmldomain.com/
http://bluespherewatertechnology.com/wpbluesphere/cost-per-thousand-a-discussion-of-water-treatment-technology/
And, if you go to Austep's website, the company lists its USA headquarters at this very familiar address:
Austep S.p.A.
via Mecenate, 76/45
20138 Milano (MI) - Italy
Tel. +39 02 509 94 71
E-mail: info@austep.com
E-mail Administrative Dept.: fornitori@austep.com
AUSTEP USA Inc.
301 McCullough Drive
Charlotte NC 28262
Ph. +1 704 460-6191 - +1 704 421-4140
So, do I think the reverse split will take place? Absolutely, but Blue Sphere may very well become the PUBLIC subsidiary in a very large Private company. Austep, in one fell swoop, could swoop up existing shares of $BLSP. Then, if desired, Austep could allow itself to be acquired by $BLSP (a Reverse Triangular Merger), thus guaranteeing a vehicle to eventual consolidation of Italian bio-energy plants and gaining a foothold in the American capital markets.
Who knows? The OTC is all about speculation.
So...Is this a good RM play?
I would not be surprised to learn that the investment firm is buying.
Oh...here's one reason they are likely confident:
Track 3: Biogas & Landfill Gas
De-Risking Biogas Projects to Put Investors at Ease and Get Vital Project Capital Flowing
Hide Description
While there is growing roster of biogas projects in North America, sector proponents believe the rate of industry growth could be accelerated. Investor reluctance is often cited as a reason for this constrained growth due to a lack of familiarity amongst the investment community with anaerobic digestion technologies. Presentations on this panel will give attendees a playbook for instilling confidence with the lenders and equity providers so crucial to getting their project off the ground. The strategic use of off-take agreements, O&M contracts and independent engineering reviews will be featured.
Shlomi Palas, CEO, Blue Sphere Corporation
Financing Biogas Projects
Josh Dale, VP Project Finance, Rabobank
Project Financing 101 and How to Make an AD Project Financeable
Joel Vyduna, Manager, Luminate LLC
Biogas Project Finance: Navigating the Due Diligence Process
http://biomassconference.com/ema/DisplayPage.aspx?pageId=Agenda_Biomass_Conference___Expo#iqiuwy
Those shares have been showing on L2 since Monday. The seller, I surmise, was trying to sell at ask but couldn't because no one was buying. The issue is not Lazarus; it is EE who must promote the stock on Twitter, FB, Ihub chat rooms.
Cheese and crackers!!!!
$BLSP
Bluesphere Corp.
Just connected with Duke Energy.
Way undervalued. Hopes to RS to NASDAQ by April 15th.
Marion Lyver is still on LinkedIn as Kallo med head. She's as trustworthy as they come. Patience pays in this case. We could literally be millionaires in a day.
Ah...but listen to the research presentation. The market misunderstood semantics. And, that's why First Eagle swooped in and bought more. The CEO basically implied that no one cares about minor lung events--the major ones are pains in the arse and cause the most damage and cost the most money. The inhaled antibiotics provided a buffer of an extra two months between these ICU events.
Also, the federal govt is in talks with $ARDM to protect our soldiers from bio warfare. Govt contracts are ALWAYS a good idea. And, with Trump in the WH, I foresee big spending in anything defense.
https://event.webcasts.com/starthere.jsp?ei=1130387
You can register as independent investor.
Although, I only noted one sell and all buys on the Time/Sales table.
The company REALLY needs to sell itself better to create interest. They just can't hope to upload to NASDAQ without building up interest.
The literally announced likely revenue of 150 million in revs over 12 years as long as they don't screw up...EVERYthing.
That is huge. The company has no debt conversions and is within 12-16 weeks of having no shareholder deficiencies on balance sheet.
Options are slated for .576 and warrants for .0928.
I do hope traders begin providing some much needed liquidity here. I noticed that Arxis Capital joined the MMs today. My hunch is that they are trying better to create some interest in the stock because most holders are not buying and are, for the most part, are not selling.
I expect a wild swing upwards once MM computer programs have been primed for maximum profit.
Target in the next month is .12--a 100% gain that would garner trader radars. Traders are needed to Vault into the Nasdaq. Period.
jmho
I think the MMs are shaking the tree to buy low.
This stock is so undervalued!!
2 month reduction in SEVERE pulmonary events.
In other words, severe costs more money. Preventing them SAVES Money.
I listened to webcast and learned a lot.
Been sitting on sidelines for years. I joined in today. I sold Grifols and put $$$ in $ARDM.
https://event.webcasts.com/viewer/event.jsp?ei=1130387
Biotechs are consolidating like hotcakes. Good news for $CBAY!
I am not a fan of extreme aged wines, so I do wish Cecil and co. would hurry up.
Agreed, but why release toward the close of trading?
Shorty will get burned.
European Med Association approves Stage 3 trials. Gonna be good!!!!
$CBAY will rock your world!
http://www.biotuesdays.com/briefs/2016/8/12/roth-ups-cymabay-price-target-to-6
Roth was proven correct! BUY!
$EAPH seems poised for growth!
I bought at .09 and am still holding 3 years later. I more than recouped my losses on paper by averaging down a bit.
I tend to invest in companies I like.
My guess is that the co may hold conference calls with investors and investment community.
Getting Excited!!!
You know, I have been doing a little research on Gideon Richter.
Note the following from the company's website:
ABOUT US
Gedeon Richter is a European innovation-driven speciality pharmaceutical company with products distributed in more than 100 countries worldwide. We are one of the few companies in the world to offer a comprehensive gynaecological portfolio.
Plus, the company has a line of products that I think may benefit from transdermal solutions: (see bold)
nonprescription products
?????????????????????????????????????????????
Note that the page is first patients was informing patients! The information presented here is not applicable to set up their own diagnosis. The symptoms are detected, consult your doctor!
anti-allergy product (Zilola)
Mother-baby vitamins (Gravida)
An anti nausea (Daedalon)
Preparations of indigestion resulting enzyme deficiency (Dipankrin)
Analgesic and antipyretic tablet (Kalmopyrin)
antifungal preparations (Terbisil cream)
medication for the treatment of heartburn and stomach acid overproduction (Quamatel mini)
An anti-fever (Aqua Maris nasal spray)
An anti-fever (Aqua Maris nasal spray strong)
Wound care products (gels Curiosa)
Ophthalmic products (Ophylosa eye drops)
Heart and preparation for the healthy functioning of the circulatory system (Panangin)
You had a typo there bud....70!!!!!
No, but generic drug manufacturing using their transdermal delivery would add value. Plus, Canada has strict quality control, so they just might cut into the Asian market share.
Maybe not Fortune 500, but Russell 2000.
Which begs the question: What's up? These buys are not just mom and pop investors moving the needle here. Something big is happening here. Jmho
Does tbe co still own oil wells?
When this stock hits $80 per share, I will break even.
Scam!!!!
Tomorrow would be a great day for news, $KALO!
So, the profits would no longer be split 50/50. That would be accretive to the bottom line.
Awesome.
Really? Something is up. Someone on here mentioned a bidding war b/w Gideon and Bayer. Maybe there is something to that rumor.
Missed that one. Thanks!
Hey y'all, check out $EAPH!
It is definitely growing momentum. See latest press release:
https://www.otcmarkets.com/stock/EAPH/news/Easton-Pharmaceuticals-and-Partner-BMV-Medica-Sign-First-Sales--amp--Marketing-Agreement-with-European-Based--Multi-National-Pharmaceutical-Company--Gedeon-Richter--For-Women-s-Health--Sales--amp--Marketing-of-its-Gynofit----Lactic-Acid-Gel-Treatment-of-B?id=146975&b=y
Easton has the potential to grow much larger! This stock should hit a dime in the new year.
Disclaimer: I have held onto my $EAPH shares for 3 years and recently added much more.
Easton Pharmaceuticals, Inc. (formerly LAM)
(A Development Stage Company)
Financial Statements For Quarter Ended September 30, 2016
Prepared By Management Without Audit
Q3 – September 30, 2016 Page 18
Generic Cancer Drugs: The cancer drugs: Biolyse Pharma Corporation the manufacturer of these drugs
initially entered into an exclusive distribution agreement with BMV Medica, and BMV in turn then
entered into a 50/50 profit split with Easton Pharmaceuticals for the full line of Biolyse-manufactured
drugs beginning with Paclitaxel and docetaxel two of the most-commonly prescribed cancer (oncology)
drugs in use today,- prescribed for breast, lung, colon and several other cancers. Both drugs are generic
with manufacturers from the US, Canada, Mexico, Europe and India vying for a total market of several
Billion dollars for these two drugs.
Easton/BMV’s market is Latin America, where, starting in Mexico, Canadian-manufactured drugs have
an advantage over the Asian-origin drugs, because of NAFTA (North American Free Trade Agreement),
allowing Canadian manufacturers to enter into the lucrative national tenders. In addition Canadianmanufactured
cancer drugs also have a perceived advantage in quality over the Asian-manufactured
counterparts. Easton/BMV have in-licensed the exclusive rights for the full line of Biolyse-manufactured
drugs expected to reach in excess of over 30 drug offerings in the coming five years.
Thanks for this post. Clearly, medical marijuana is big business and Easton seems to be carving out pie pieces.
Lazarus has been above board. If you check them out, you will see that they establish positions and then begin releasing positive write ups to followers on Seeking Alpha to help promote investments. They will not allow shares to sink as it makes them look bad.
The VS Sense is the real deal. Easton is finally growing into a powerhouse.
They keep buying and reporting to SEC. If they buy up the float, shares become valuable. ????
A million share buy gets us to a nickel.
*$leeping Giant
Level 2 suggests thinness all the way to.
05.
Easton very well might be a Ealing giant.